306296-99-1Relevant academic research and scientific papers
PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
-
Page/Page column 22, (2010/02/12)
The use is described of CCR5 antagonists of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroary
Piperazine derivatives useful as CCR5 antagonists
-
Page column 35, (2010/02/05)
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten
Tagat,Steensma,McCombie,Nazareno,Lin,Neustadt,Cox,Xu,Wojcik,Murray,Vantuno,Baroudy,Strizki
, p. 3343 - 3346 (2007/10/03)
Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm
